Irritable Bowel Syndrome (IBS) - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB503240477

Publication Date:

March 22, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
The global market for Irritable Bowel Syndrome (IBS) was estimated to be worth US$ 4737.2 million in 2023 and is forecast to a readjusted size of US$ 12740 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Irritable Bowel Syndrome (IBS), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Irritable Bowel Syndrome (IBS) by region & country, by Type, and by Application.
The Irritable Bowel Syndrome (IBS) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Irritable Bowel Syndrome (IBS).
麻豆原创 Segmentation
By Company
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
Segment by Type:
IBS-D Drug
IBS-C Drug
Others
Segment by Application
Women
Men
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Irritable Bowel Syndrome (IBS) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Irritable Bowel Syndrome (IBS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Irritable Bowel Syndrome (IBS) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Irritable Bowel Syndrome (IBS) Product Introduction
1.2 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size Forecast
1.3 Irritable Bowel Syndrome (IBS) 麻豆原创 Trends & Drivers
1.3.1 Irritable Bowel Syndrome (IBS) Industry Trends
1.3.2 Irritable Bowel Syndrome (IBS) 麻豆原创 Drivers & Opportunity
1.3.3 Irritable Bowel Syndrome (IBS) 麻豆原创 Challenges
1.3.4 Irritable Bowel Syndrome (IBS) 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Irritable Bowel Syndrome (IBS) Players Revenue Ranking (2023)
2.2 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2019-2024)
2.3 Key Companies Irritable Bowel Syndrome (IBS) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Irritable Bowel Syndrome (IBS) Product Offered
2.5 Key Companies Time to Begin Mass Production of Irritable Bowel Syndrome (IBS)
2.6 Irritable Bowel Syndrome (IBS) 麻豆原创 Competitive Analysis
2.6.1 Irritable Bowel Syndrome (IBS) 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Irritable Bowel Syndrome (IBS) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome (IBS) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 IBS-D Drug
3.1.2 IBS-C Drug
3.1.3 Others
3.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type
3.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value, by Type (2019-2030)
3.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Women
4.1.2 Men
4.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application
4.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value, by Application (2019-2030)
4.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region
5.1.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2019-2024)
5.1.3 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2025-2030)
5.1.4 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
5.2.2 North America Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
5.3.2 Europe Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
5.4.2 Asia Pacific Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
5.5.2 South America Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
5.6.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Irritable Bowel Syndrome (IBS) Sales Value
6.3 United States
6.3.1 United States Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.3.2 United States Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.4.2 Europe Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.5.2 China Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.6.2 Japan Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.7.2 South Korea Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.8.2 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Irritable Bowel Syndrome (IBS) Sales Value, 2019-2030
6.9.2 India Irritable Bowel Syndrome (IBS) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Irritable Bowel Syndrome (IBS) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bausch Health
7.1.1 Bausch Health Profile
7.1.2 Bausch Health Main Business
7.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Products, Services and Solutions
7.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2019-2024)
7.1.5 Bausch Health Recent Developments
7.2 Allergan
7.2.1 Allergan Profile
7.2.2 Allergan Main Business
7.2.3 Allergan Irritable Bowel Syndrome (IBS) Products, Services and Solutions
7.2.4 Allergan Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2019-2024)
7.2.5 Allergan Recent Developments
7.3 Takeda
7.3.1 Takeda Profile
7.3.2 Takeda Main Business
7.3.3 Takeda Irritable Bowel Syndrome (IBS) Products, Services and Solutions
7.3.4 Takeda Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2019-2024)
7.3.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
7.4 Sucampo Pharmaceuticals (Mallinckrodt)
7.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Profile
7.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Main Business
7.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Products, Services and Solutions
7.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2019-2024)
7.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
7.5 Sebela Pharmaceuticals Inc
7.5.1 Sebela Pharmaceuticals Inc Profile
7.5.2 Sebela Pharmaceuticals Inc Main Business
7.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Products, Services and Solutions
7.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2019-2024)
7.5.5 Sebela Pharmaceuticals Inc Recent Developments
7.6 Astellas Pharmaceuticals
7.6.1 Astellas Pharmaceuticals Profile
7.6.2 Astellas Pharmaceuticals Main Business
7.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Products, Services and Solutions
7.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue (US$ Million) & (2019-2024)
7.6.5 Astellas Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Irritable Bowel Syndrome (IBS) Industrial Chain
8.2 Irritable Bowel Syndrome (IBS) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Irritable Bowel Syndrome (IBS) Sales Model
8.5.2 Sales Channel
8.5.3 Irritable Bowel Syndrome (IBS) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.